Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
RasCal Therapeutics, Inc.
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
Eli Lilly and Company
Pfizer
Fred Hutchinson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Tomsk National Research Medical Center of the Russian Academy of Sciences
M.D. Anderson Cancer Center
University Hospital Heidelberg
Alterome Therapeutics, Inc.
University Health Network, Toronto
City of Hope Medical Center
Xencor, Inc.
Cedars-Sinai Medical Center
Boehringer Ingelheim
Amgen
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Whitehawk Therapeutics, Inc.
Shanghai Chest Hospital
ViroMissile, Inc.
Massachusetts General Hospital
Replimune Inc.
Ohio State University Comprehensive Cancer Center
Pfizer
M.D. Anderson Cancer Center
Pfizer
University of Maryland, Baltimore
Pfizer
M.D. Anderson Cancer Center
Tizona Therapeutics, Inc
National Institutes of Health Clinical Center (CC)
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Ohio State University Comprehensive Cancer Center
Clasp Therapeutics, Inc.
Dana-Farber Cancer Institute
Mayo Clinic
H. Lee Moffitt Cancer Center and Research Institute
Baylor College of Medicine
Mayo Clinic
Rutgers, The State University of New Jersey
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Roswell Park Cancer Institute
Revolution Medicines, Inc.
Pheon Therapeutics
St. Joseph's Healthcare Hamilton